Skip to main content

Table 2 Characteristics of the analyzed studies on endometrial transcriptomics for infertile women in natural and stimulated Cycle

From: 15 years of transcriptomic analysis on endometrial receptivity: what have we learnt?

First author and reference Participants population N of patients Age Comparative Region Array First sample (day, n) Second sample (day, n) N of genes up-regulated N of genes down regulated
Infertile women
 Natural cycles
  Koler et al. [41] women with unexplained infertility + fertile women 32 19-40 Infertile vs fertile Europe Array-Ready Oligo SetTM for the Human Genome Version 3.0 (Operon) cd21
Infertile women (n = 4)
fertile women (n = 12
25 288
  Altmae et al. [31] women with unexplained infertility Infertile women (n = 4)
Fertile women (n = 4)
30.5+4.0
31.8+3.8
Infertile vs fertile Europe Whole Human Genome Oligo Microarray (Agilent Technologies) LH +7
Infertile women (n = 4)
fertile women (n = 5)
145 115
  Koot et al. [34] women experiencing RIF 115 26-39 Infertile vs fertile Europe Human whole genome gene expression microarrays V2 (Agilent) mid-luteal phase
n = 115
303 genes predictive of RIF 303 genes predictive of RIF
 Stimulated cycles
  Liu et al. [25] Infertile women with normal menstrual cycles 47 26 -38 NC vs CCOS Hong Kong HG_U133A (Affymetrix) LH+7
n = 5
hCG+7
n = 8
244 159
  Ruiz-Alonso et al. [36] Patients with repeated implantation failure 110 23-51 RIF vs controls
pWOI/Pwoi delayed/pWOI advanced
Europe homemade ERA P+5
LH+7
- -
  Altmae et al. [19] Patients with repeated implantation failure 15 30.2 ± 4.3 Infertile vs fertile Europe Whole Human Genome Oligo Microarray (Agilent Technologies LH+7 (n = 5)
P+6 (n = 5)
443 446
  Haouzi et al. [33] Oocyte-donation recipient patients
RIF patients
39 31-50 NC vs HRT hormone replacement therapy Europe HGU133 plus 2.0 (Affymetrix) LH+7 (n = 7)
P+5 (n = 7)
1814 477
  1. Abbreviations: EP Early-proliferative, ES Early-Secretory, Ag Agonist, Atg Antagonist, LH+ LH surge + days, NC Natural cycle, COH Controlled ovarian hyperstimulation, MS mid-secretory, CCOS Controlled ovarian stimulation, PP proliferative phase, P+ Progesterone+ days, HRT hormone replacement therapy, pWO personalised window of implantation